Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on evaluating giredestrant versus physician's choice of adjuvant endocrine therapy for estrogen receptor-positive, HER2-negative e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Giredestrant (giredestrant)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Early Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING